Benefits Investigation (BI)

Rituxan^® Access Solutions can help your practice facilitate a benefits investigation (BI) on behalf of your Rituxan^® (rituximab) patient before treatment starts. This way, you can be sure your patient's health plan coverage for some or all of the costs associated with Rituxan treatment. The BI can also determine if patient assistance might be needed.

To have Rituxan Access Solutions conduct a BI, all you need to do is request our assistance on the signed Statement of Medical Necessity (SMN) form.

By conducting a BI, you know what is covered before your practice begins treatment. Also, some health plans require a prior authorization (PA) for the use of Rituxan. The BI helps determine if a PA is needed.

In addition, you can use the BI to see if your patient might qualify for assistance through the Genentech^® Access to Care Foundation (GATCF). By completing the GATCF Eligibility Screening while conducting the BI, you open this option to the patient who might be uninsured or has no coverage for Rituxan.

Note: This description of a BI is for informational purposes only. The completion and submission of a BI are the responsibility of the patient and your office. Rituxan Access Solutions makes no representation or guarantee concerning reimbursement or coverage for any service or item.

INDICATIONS

RITUXAN^® (Rituximab) is indicated for the treatment of patients with:

Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Previously untreated CD20-positive CLL in combination with FC chemotherapy
Previously treated CD20-positive CLL in combination with FC chemotherapy

People with serious infections should not receive RITUXAN

IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).

RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.

The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.

Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including the Medication Guide.

Rituxan^® and its logo are trademarks of Biogen Idec, Inc.
The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.